808 related articles for article (PubMed ID: 27212429)
21. Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan.
Saleem AF; Mach O; Quadri F; Khan A; Bhatti Z; Rehman NU; Zaidi S; Weldon WC; Oberste SM; Salama M; Sutter RW; Zaidi AK
Vaccine; 2015 Jun; 33(24):2757-63. PubMed ID: 25917673
[TBL] [Abstract][Full Text] [Related]
22. Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame.
Gaensbauer JT; Gast C; Bandyopadhyay AS; O'Ryan M; Saez-Llorens X; Rivera L; Lopez-Medina E; Melgar M; Weldon WC; Oberste MS; Rüttimann R; Clemens R; Asturias EJ
Clin Infect Dis; 2018 Oct; 67(suppl_1):S57-S65. PubMed ID: 30376095
[TBL] [Abstract][Full Text] [Related]
23. Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
Resik S; Tejeda A; Mach O; Fonseca M; Diaz M; Alemany N; Heng Hung L; Aleman Y; Mesa I; Garcia G; Sutter RW
Clin Infect Dis; 2018 Oct; 67(suppl_1):S51-S56. PubMed ID: 30376088
[TBL] [Abstract][Full Text] [Related]
24. Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
Snider CJ; Zaman K; Wilkinson AL; Binte Aziz A; Yunus M; Haque W; Jones KAV; Wei L; Estivariz CF; Konopka-Anstadt JL; Mainou BA; Patel JC; Lickness JS; Pallansch MA; Wassilak SGF; Steven Oberste M; Anand A
Vaccine; 2023 Sep; 41(41):6083-6092. PubMed ID: 37652822
[TBL] [Abstract][Full Text] [Related]
25. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.
Brickley EB; Strauch CB; Wieland-Alter WF; Connor RI; Lin S; Weiner JA; Ackerman ME; Arita M; Oberste MS; Weldon WC; Sáez-Llorens X; Bandyopadhyay AS; Wright PF
J Infect Dis; 2018 Jan; 217(3):371-380. PubMed ID: 29304199
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial.
Zaman K; Estívariz CF; Morales M; Yunus M; Snider CJ; Gary HE; Weldon WC; Oberste MS; Wassilak SG; Pallansch MA; Anand A
Lancet Infect Dis; 2018 Jun; 18(6):657-665. PubMed ID: 29571817
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of sequential poliovirus vaccination schedules with different strains of poliomyelitis vaccines in Chongqing, China: a cross-sectional survey.
Xu J; Wang Q; Kuang S; Rong R; Zhang Y; Fu X; Tang W
Hum Vaccin Immunother; 2021 Jul; 17(7):2125-2131. PubMed ID: 33759702
[TBL] [Abstract][Full Text] [Related]
28. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.
Anand A; Zaman K; Estívariz CF; Yunus M; Gary HE; Weldon WC; Bari TI; Steven Oberste M; Wassilak SG; Luby SP; Heffelfinger JD; Pallansch MA
Vaccine; 2015 Nov; 33(48):6816-22. PubMed ID: 26476367
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.
Wilkinson AL; Zaman K; Hoque M; Estivariz CF; Burns CC; Konopka-Anstadt JL; Mainou BA; Kovacs SD; An Q; Lickness JS; Yunus M; Snider CJ; Zhang Y; Coffee E; Abid T; Wassilak SGF; Pallansch MA; Oberste MS; Vertefeuille JF; Anand A
Lancet Infect Dis; 2023 Sep; 23(9):1062-1071. PubMed ID: 37178706
[TBL] [Abstract][Full Text] [Related]
31. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
Van Damme P; De Coster I; Bandyopadhyay AS; Revets H; Withanage K; De Smedt P; Suykens L; Oberste MS; Weldon WC; Costa-Clemens SA; Clemens R; Modlin J; Weiner AJ; Macadam AJ; Andino R; Kew OM; Konopka-Anstadt JL; Burns CC; Konz J; Wahid R; Gast C
Lancet; 2019 Jul; 394(10193):148-158. PubMed ID: 31174831
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.
Rivera Mejía L; Peña Méndez L; Bandyopadhyay AS; Gast C; Mazara S; Rodriguez K; Rosario N; Zhang Y; Mainou BA; Jimeno J; Aguirre G; Rüttimann R
Lancet Infect Dis; 2024 Mar; 24(3):275-284. PubMed ID: 38109921
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM
Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307
[TBL] [Abstract][Full Text] [Related]
34. Comparison of IPV to tOPV week 39 boost of primary OPV vaccination in Indian infants: an open labelled randomized controlled trial.
Kanungo S; Kim DR; Haldar B; Snider C; Nalavade U; Kim SA; Park JY; Sinha A; Mallick AH; Manna B; Sur D; Nandy RK; Deshpande JM; Czerkinsky C; Wierzba TF; Petri WA; Ali M; Dey A
Heliyon; 2017 Jan; 3(1):e00223. PubMed ID: 28194449
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.
Bandyopadhyay AS; Modlin JF; Wenger J; Gast C
Clin Infect Dis; 2018 Oct; 67(suppl_1):S35-S41. PubMed ID: 30376081
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
De Coster I; Leroux-Roels I; Bandyopadhyay AS; Gast C; Withanage K; Steenackers K; De Smedt P; Aerssens A; Leroux-Roels G; Oberste MS; Konopka-Anstadt JL; Weldon WC; Fix A; Konz J; Wahid R; Modlin J; Clemens R; Costa Clemens SA; Bachtiar NS; Van Damme P
Lancet; 2021 Jan; 397(10268):39-50. PubMed ID: 33308429
[TBL] [Abstract][Full Text] [Related]
37. Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.
Erdem R; De Coster I; Withanage K; Mercer LD; Marchant A; Taton M; Cools N; Lion E; Cassels F; Higgins D; Ivinson K; Locke E; Mahmood K; Wright PF; Gast C; White JA; Ackerman ME; Konopka-Anstadt JL; Mainou BA; Van Damme P
Vaccine; 2023 Mar; 41(10):1657-1667. PubMed ID: 36746739
[TBL] [Abstract][Full Text] [Related]
38. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms].
Ye H; Huang T; Ying ZF; Li GL; Che YC; Zhao ZM; Wang JF; Yang XL; Shi L; Jiang RJ; Liu XC; Mo ZJ; Li CG; Yang JS
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jan; 52(1):43-49. PubMed ID: 29334707
[No Abstract] [Full Text] [Related]
39. Polio eradication. Efficacy of inactivated poliovirus vaccine in India.
Jafari H; Deshpande JM; Sutter RW; Bahl S; Verma H; Ahmad M; Kunwar A; Vishwakarma R; Agarwal A; Jain S; Estivariz C; Sethi R; Molodecky NA; Grassly NC; Pallansch MA; Chatterjee A; Aylward RB
Science; 2014 Aug; 345(6199):922-5. PubMed ID: 25146288
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B
Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]